Assessment of Minimal Residual Disease in Standard-Risk AML

2016822 citationsJournal Articlebronze Open Access

Authors

Adam Ivey · Guy's Hospital

Robert K. Hills · Cardiff University

Michael A. Simpson

Jelena Jovanović

Amanda Gilkes · Cardiff University

Angela Grech · Oxford University Hospitals NHS Trust

Yashma Patel · University College London

Neesa Bhudia ·

Abstract

The presence of minimal residual disease, as determined by quantitation of NPM1-mutated transcripts, provided powerful prognostic information independent of other risk factors. (Funded by Bloodwise and the National Institute for Health Research; Current Controlled Trials number, ISRCTN55675535.).

Topics & Keywords

Acute Myeloid Leukemia Research Retinoids in leukemia and cellular processes Acute Lymphoblastic Leukemia research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 374, Issue 5, pp. 422-433

DOI: 10.1056/nejmoa1507471

Field-Weighted Citation Impact: 77.36